AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18359865 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (400 mg to 1,200 mg) plus temozolomide (150-200 mg/m² per day on days 4-8)
Number of subjects: 65
Study 18359865 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (1,000 mg) plus temozolomide (150-200 mg/m² per day on days 4-8)
Number of subjects: 65
Study 15076235 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 52
Study 15076235 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study 11559726 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care
Number of subjects: 434
Study 11559726 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 434
Study 9777766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus mid-potency corticosteroid cream
Number of subjects: 300
Study 9777766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus high-potency corticosteroid cream
Number of subjects: 300
Study 9777766 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene 0.1% gel plus placebo cream
Number of subjects: 300
Study 7835452 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac and gentamicin combination
Number of subjects: 80
Study 7835452 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone and neomycin combination
Number of subjects: 80
Study 3035303 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study 3035303 — intervention group
Group type: COMPARATOR
Intervention: 3H‐clonidine and 3H‐imipramine binding
Number of subjects: 0
Study 30904939 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (up to 1 g twice daily)
Number of subjects: 27
Study 29693650 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (NaPB; 7.15 g•m‐2BSA•day‐1)
Number of subjects: 0
Study 29693650 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoate (NaBz; 5.5 g•m‐2BSA•day‐1)
Number of subjects: 0
Study 29693650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (MIX arm; 3.575 g NaPB and 2.75 g NaBz•m‐2BSA•day‐1)
Number of subjects: 0
Study 29693650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (MIX arm)
Number of subjects: 0
Study 29693650 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate (NaPB)
Number of subjects: 0
Study 27620995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral simvastatin 40 mg once daily for 3-7 days before surgery
Number of subjects: 144
Study 27620995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 27620995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral simvastatin 40 mg
Number of subjects: 144
Study 27620995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral simvastatin
Number of subjects: 144
Study 25080284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedunculopontine nucleus area stimulation (off stimulation)
Number of subjects: 6
Study 25080284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedunculopontine nucleus area stimulation
Number of subjects: 6
Study 25080284 — intervention group
Group type: COMPARATOR
Intervention: Levodopa intake
Number of subjects: 6
Study 25080284 — intervention group
Group type: COMPARATOR
Intervention: Subthalamic nucleus stimulation
Number of subjects: 6
Study 25080284 — intervention group
Group type: COMPARATOR
Intervention: Combination of levodopa intake and subthalamic nucleus stimulation
Number of subjects: 6
Study 22574592 — intervention group
Group type: EXPERIMENTAL
Intervention: Biqi Capsule (BQC)
Number of subjects: 138
Study 22574592 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 138
Study 22574592 — intervention group
Group type: EXPERIMENTAL
Intervention: BQC combined with MTX
Number of subjects: 138
Study 22574592 — intervention group
Group type: COMPARATOR
Intervention: Control (BQC or MTX alone)
Number of subjects: 138
Study 19604584 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive behaviour therapy (CBT) treatment program, 10 sessions over 20 weeks.
Number of subjects: 60
Study 17284737 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (500 additional kcal)
Number of subjects: 52
Study 17284737 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (500 additional kcal)
Number of subjects: 52
Study 17284737 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet (500 additional kcal)
Number of subjects: 52
Study 17284737 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (20% protein, 30% fat, 50% carbohydrate)
Number of subjects: 52
Study 15857738 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium-89
Number of subjects: 35
Study 15857738 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (FEM=5-FU, epirubicin, and mitomycin C)
Number of subjects: 35
Study 11586809 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 0
Study 11586809 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9392310 — intervention group
Group type: EXPERIMENTAL
Intervention: GST monitoring reported daily to the ward (reporting group)
Number of subjects: 49
Study 7709992 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide delivered via Turbuhaler
Number of subjects: 102
Study 7709992 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) with volumatic spacer
Number of subjects: 102
Study 3109602 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose solution with 6 g salt
Number of subjects: 8
Study 3109602 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled macaroni with 6 g salt
Number of subjects: 8
Study 3109602 — intervention group
Group type: COMPARATOR
Intervention: 20% glucose solution without salt
Number of subjects: 8
Study 3109602 — intervention group
Group type: COMPARATOR
Intervention: Boiled macaroni without salt
Number of subjects: 8
Study 31506074 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) once daily for 20 minutes, electrical current increased up to 70 mA until contraction detected.
Number of subjects: 21
Study 28414617 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted narrative intervention
Number of subjects: 316
Study 28414617 — intervention group
Group type: COMPARATOR
Intervention: Control narrative (not explicitly mentioned)
Number of subjects: 316
Study 26686043 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg to 300 mg daily)
Number of subjects: 98
Study 26686043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 26686043 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 98
Study 23485887 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD; 0.3 g/kg bw/day)
Number of subjects: 32
Study 23485887 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LPD; 0.6 g/kg bw/day)
Number of subjects: 32
Study 23485887 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 32
Study 23485887 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis patients (HD)
Number of subjects: 32
Study 23485887 — intervention group
Group type: COMPARATOR
Intervention: Chronic kidney disease (CKD) patients
Number of subjects: 32
Study 21599433 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week
Number of subjects: 213
Study 21599433 — intervention group
Group type: COMPARATOR
Intervention: Deferiprone alone 75 mg/kg 7 days/week
Number of subjects: 213
Study 19439117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target group, blood glucose 6.2 to 8.3 mmol/L)
Number of subjects: 27
Study 19439117 — intervention group
Group type: COMPARATOR
Intervention: Routine insulin therapy (routine group, blood glucose 4.1 to 6.1 mmol/L)
Number of subjects: 27
Study 17012299 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day rosuvastatin therapy
Number of subjects: 35
Study 17012299 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study 15138798 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-alginate insert with 0% hydroxyethylcellulose
Number of subjects: 24
Study 15138798 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-alginate insert with 5% hydroxyethylcellulose
Number of subjects: 24
Study 15138798 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-alginate insert with 30% hydroxyethylcellulose
Number of subjects: 24
Study 11319198 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPE-susceptible subjects
Number of subjects: 30
Study 11319198 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPE-susceptible subjects with HAPE
Number of subjects: 30
Study 11319198 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPE-susceptible subjects without HAPE
Number of subjects: 30
Study 11319198 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 9272760 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant treatment
Number of subjects: 45
Study 9272760 — intervention group
Group type: COMPARATOR
Intervention: Site raters
Number of subjects: 45
Study 8509525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (12-week placebo-controlled, double-blind trial)
Number of subjects: 0
Study 8509525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12-week placebo-controlled, double-blind trial)
Number of subjects: 0
Study 31096099 — intervention group
Group type: EXPERIMENTAL
Intervention: High mean arterial pressure (MAP) target ≥ 85 mmHg
Number of subjects: 18
Study 31096099 — intervention group
Group type: COMPARATOR
Intervention: Low mean arterial pressure (MAP) target 65-70 mmHg
Number of subjects: 18
Study 29927398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (2 tablets 2 times a day)
Number of subjects: 156
Study 29927398 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (Control)
Number of subjects: 156
Study 26733479 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU per week for 12 months
Number of subjects: 472
Study 26733479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 25077847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 10633
Study 25077847 — intervention group
Group type: COMPARATOR
Intervention: Non-MBCT group therapy
Number of subjects: 10633
Study 22284022 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with varying levels of depressive symptoms (NO, SLOW, GO)
Number of subjects: 72
Study 22284022 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CDRS-R scores
Number of subjects: 72
Study 22284022 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline functioning
Number of subjects: 72
Study 22284022 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CDRS and MRS scores
Number of subjects: 72
Study 22284022 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS scores over time
Number of subjects: 72
Study 22284022 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing MRS scores
Number of subjects: 72
Study 22049891 — intervention group
Group type: EXPERIMENTAL
Intervention: Gargling with ketamine 50 mg in drinking water 30 ml for 30 s, 5 min before induction of anaesthesia
Number of subjects: 40
Study 22049891 — intervention group
Group type: COMPARATOR
Intervention: Gargling with drinking water 30 ml
Number of subjects: 40
Study 18949039 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouping search algorithm
Number of subjects: 0
Study 15753530 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplement of 25 mg daily for 14 days
Number of subjects: 18
Study 15753530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14608136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary beta radiation (90Strontium/90Yttrium)
Number of subjects: 239
Study 14608136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 10569419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg BID for 3-8 days preoperatively
Number of subjects: 20
Study 10569419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg BID for 9-14 days preoperatively
Number of subjects: 20
Study 9059267 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (10, 12, or 15 Gy of 6 MV photons)
Number of subjects: 41
Study 9059267 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-randomised observation)
Number of subjects: 41
Study 1724941 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with arginine, menhaden oil, and RNA
Number of subjects: 0
Study 1724941 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally complete enteral formula (control)
Number of subjects: 0
Study 6349560 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group A and group C meningococcal polysaccharide vaccine
Number of subjects: 438
Study 6349560 — intervention group
Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 438
Study 30855463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 μg/kg
Number of subjects: 75
Study 30855463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.1 μg/kg
Number of subjects: 75
Study 30855463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.05 μg/kg
Number of subjects: 75
Study 30855463 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 0 μg/kg (control group)
Number of subjects: 75
Study 30855463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.15 μg/kg
Number of subjects: 75
Study 30855463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (all dosages)
Number of subjects: 75
Study 30855463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 75
Study 27609065 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 0
Study 27609065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26757356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based walking intervention for 12 weeks, increasing walking distance by 500 steps per week
Number of subjects: 112
Study 26757356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study 24314857 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm saline mouth rinse six times daily (Group A)
Number of subjects: 120
Study 24314857 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm saline mouth rinse twice daily (Group B)
Number of subjects: 120
Study 24314857 — intervention group
Group type: COMPARATOR
Intervention: No saline mouth rinse (Group C)
Number of subjects: 120
Study 21508663 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorous magnetic resonance spectroscopy (31P MRS)
Number of subjects: 15
Study 19308417 — intervention group
Group type: EXPERIMENTAL
Intervention: MR spectroscopy (MRS)
Number of subjects: 17
Study 19308417 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetisation transfer imaging (MTI)
Number of subjects: 17
Study 19308417 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (treatment initiation)
Number of subjects: 17
Study 19308417 — intervention group
Group type: EXPERIMENTAL
Intervention: NAWM
Number of subjects: 17
Study 17279280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional guidance in the first year of life with monthly follow‐up home visits
Number of subjects: 369
Study 17279280 — intervention group
Group type: COMPARATOR
Intervention: Control group with visits at 6 and 12 months, without nutritional intervention
Number of subjects: 369
Study 15599697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 637
Study 15599697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 637
Study 15599697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study 11368699 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064
Study 9852628 — intervention group
Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF) 30 g/day for 28 days
Number of subjects: 10
Study 9852628 — intervention group
Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF)
Number of subjects: 10
Study 7991338 — intervention group
Group type: EXPERIMENTAL
Intervention: Field sobriety tests
Number of subjects: 14
Study 7991338 — intervention group
Group type: COMPARATOR
Intervention: Normal-abilities tests
Number of subjects: 14
Study 2465457 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (700 mg approximately)
Number of subjects: 80
Study 2465457 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 31619112 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-perceptual ratings of vocal tremor severity by 4 female audiologists on a continuous 10-cm scale.
Number of subjects: 56
Study 31619112 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic markers of vocal tremor including 12 acoustic measures of rate, extent and perturbation of fundamental frequency (f0), and intensity level (IL) modulation.
Number of subjects: 56
Study 31619112 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic model of vocal tremor severity based on the 12 acoustic measures.
Number of subjects: 56
Study 27911869 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF regimen (paclitaxel 135 mg/m2 iv on day 1, oxaliplatin 100 mg/m2 iv on day 1, fluorouracil 500 mg/m2 continuous iv on day 1-5)
Number of subjects: 60
Study 27911869 — intervention group
Group type: COMPARATOR
Intervention: SOX regimen (oxaliplatin 130 mg/m2 iv on day 1, S-1 40 mg/60mg orally twice/day on days 1-14)
Number of subjects: 60
Study 25387728 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 12 months
Number of subjects: 424
Study 25387728 — intervention group
Group type: COMPARATOR
Intervention: Successful aging education group (control)
Number of subjects: 424
Study 25387728 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 424
Study 23307011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2MVCs performed immediately (0d) before MaxECC
Number of subjects: 65
Study 23307011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2MVCs performed 2 days (2d) before MaxECC
Number of subjects: 65
Study 23307011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2MVCs performed 4 days (4d) before MaxECC
Number of subjects: 65
Study 23307011 — intervention group
Group type: COMPARATOR
Intervention: Control group (no 2MVCs)
Number of subjects: 65
Study 23307011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2MVCs performed 7 days (7d) before MaxECC
Number of subjects: 65
Study 21300736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta‐1a (IFNβ‐1a) treatment
Number of subjects: 158
Study 21300736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 19889831 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK with 0.002% MMC for 1 min
Number of subjects: 44
Study 19889831 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 44
Study 16864757 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of recombinant human thyrotropin
Number of subjects: 57
Study 16864757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 12749545 — intervention group
Group type: COMPARATOR
Intervention: Driving after controlled habitual sleep (8.5 hours) (Road 1)
Number of subjects: 10
Study 12749545 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving after reduced sleep (2 hours) (Road 2)
Number of subjects: 10
Study 12749545 — intervention group
Group type: COMPARATOR
Intervention: Laboratory after controlled habitual sleep (8.5 hours)
Number of subjects: 10
Study 11019779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (free day care, rehab program, mood induction interventions)
Number of subjects: 260
Study 11019779 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 260
Study 8791047 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of neo‐adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks)
Number of subjects: 111
Study 8791047 — intervention group
Group type: COMPARATOR
Intervention: Immediate radical prostatectomy
Number of subjects: 111
Study 1455326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Ibumetin)
Number of subjects: 120
Study 1455326 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol/codeine combination (Citodon)
Number of subjects: 120
Study 2861220 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 55
Study 2861220 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole + Beclomethasone dipropionate
Number of subjects: 55
Study 2861220 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 55
Study 29991375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-offset community-supported agriculture (CO-CSA) program
Number of subjects: 53
Study 28881347 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (500 mg capsules, 2 capsules daily for 12 weeks)
Number of subjects: 61
Study 28881347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 placebo capsules daily for 12 weeks)
Number of subjects: 61
Study 26216378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fluticasone propionate (2000 mcg/day)
Number of subjects: 81
Study 26216378 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone (1 mg/kg/day)
Number of subjects: 81
Study 23713756 — intervention group
Group type: EXPERIMENTAL
Intervention: HR‐VG (Healthy Relationships via video-group)
Number of subjects: 4
Study 21272339 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily for 52 weeks
Number of subjects: 2686
Study 21272339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2686
Study 18764946 — intervention group
Group type: EXPERIMENTAL
Intervention: Slim Fast Plan
Number of subjects: 293